Nemes Rush Group’s BioLife Solutions BLFS Stock Holding History

Nemes Rush Group’s Portfolio BLFS Stock Details BLFS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6	Closed	-$83	–	663
2023 Q3	$83	Buy	+6	New	+$95	﹤0.01%	643

Other funds holding BLFS

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nemes Rush Group's BLFS Position: Q4 2023 in Review

Nemes Rush Group sold out of BioLife Solutions (BLFS) in Q4 2023, closing a stake of 6 shares — an estimated $83 sold.

Nemes Rush Group first reported a position in BLFS in Q3 2023 and held it in 1 quarter. The position peaked at $83 in Q3 2023. 140 funds tracked by Wall St. Rank hold BLFS as of Q4 2023.

Nemes Rush Group reported no remaining BioLife Solutions position as of Q4 2023 after selling out during the quarter.
Nemes Rush Group sold 6 BioLife Solutions shares in Q4 2023, an estimated $83.
Nemes Rush Group first reported a position in BioLife Solutions in Q3 2023 and held it in 1 quarter.
Nemes Rush Group's BioLife Solutions position peaked at $83 in Q3 2023.
140 funds tracked by Wall St. Rank held BioLife Solutions as of Q4 2023.

Based on Nemes Rush Group's 13F filing for Q4 2023, filed 9 Feb 2024.